Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
Equillium announced that an abstract was accepted for a poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer.
The conference will be held from November 6 to 10, 2024, at the George R. Brown Convention Center in Houston, Texas. The abstract, titled Interleukin (IL)-15 and IL-21 synergistically enhance NK and CD8+ T cell responses, will be presented by Phoi Tiet, Senior Research Associate at Equillium, on November 9, 2024.
The abstract highlights the potential of IL-15 and IL-21 to augment NK and CD8 T cell activities, enhancing their proliferation and cytolytic function. This combination could be a promising approach to stimulating anti-tumor immune responses.
Equillium ha annunciato che un abstract è stato accettato per una presentazione poster durante il 39° Congresso Annuale della Società per l'Immunoterapia del Cancro.
La conferenza si terrà dal 6 al 10 novembre 2024, presso il George R. Brown Convention Center a Houston, Texas. L'abstract, intitolato Interleuchina (IL)-15 e IL-21 aumentano sinergicamente le risposte delle cellule NK e CD8+, sarà presentato da Phoi Tiet, Ricercatore Senior presso Equillium, il 9 novembre 2024.
L'abstract mette in evidenza il potenziale di IL-15 e IL-21 per potenziare le attività delle cellule NK e delle cellule T CD8, migliorando la loro proliferazione e funzione citolitica. Questa combinazione potrebbe rappresentare un approccio promettente per stimolare le risposte immunitarie anti-tumorali.
Equillium anunció que un resumen fue aceptado para una presentación de cartel en la 39ª Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer.
La conferencia se llevará a cabo del 6 al 10 de noviembre de 2024, en el George R. Brown Convention Center en Houston, Texas. El resumen, titulado Interleucina (IL)-15 e IL-21 mejoran sinérgicamente las respuestas de las células NK y CD8+, será presentado por Phoi Tiet, Asociado de Investigación Senior en Equillium, el 9 de noviembre de 2024.
El resumen destaca el potencial de IL-15 e IL-21 para aumentar las actividades de las células NK y CD8, mejorando su proliferación y función citolítica. Esta combinación podría ser un enfoque prometedor para estimular respuestas inmunitarias anti-tumorales.
Equillium은 암 면역요법 사회의 제39회 연례 회의에서 포스터 발표를 위한 초록이 채택되었다고 발표했습니다.
이번 회의는 2024년 11월 6일부터 10일까지 텍사스 휴스턴의 조지 R. 브라운 컨벤션 센터에서 개최됩니다. 초록의 제목은 인터루킨 (IL)-15와 IL-21이 NK 및 CD8+ T 세포 반응을 시너지 효과로 강화한다이며, 이날 Phoi Tiet가 Equillium의 수석 연구원으로 발표할 예정입니다.
이 초록은 IL-15와 IL-21이 NK 및 CD8 T 세포의 활동을 증진시켜 그들의 증식과 세포 용해 기능을 향상시킬 가능성을 강조합니다. 이 조합은 항종양 면역 반응을 자극하기 위한 유망한 접근 방식이 될 수 있습니다.
Equillium a annoncé qu'un résumé avait été accepté pour une présentation sous forme d'affiche lors de la 39e Réunion Annuelle de la Société pour l'Immunothérapie du Cancer.
La conférence se tiendra du 6 au 10 novembre 2024 au George R. Brown Convention Center à Houston, Texas. Le résumé, intitulé Interleukine (IL)-15 et IL-21 renforcent de manière synergique les réponses des cellules NK et CD8+, sera présenté par Phoi Tiet, Scientifique Principal chez Equillium, le 9 novembre 2024.
Le résumé met en évidence le potentiel de l'IL-15 et de l'IL-21 à augmenter les activités des cellules NK et CD8, améliorant leur prolifération et leur fonction cytolytique. Cette combinaison pourrait constituer une approche prometteuse pour stimuler les réponses immunitaires anti-tumorales.
Equillium gab bekannt, dass ein Abstract für eine Posterpräsentation auf dem 39. Jahrestreffen der Gesellschaft für Immuntherapie von Krebs akzeptiert wurde.
Die Konferenz findet vom 6. bis 10. November 2024 im George R. Brown Convention Center in Houston, Texas, statt. Das Abstract mit dem Titel Interleukin (IL)-15 und IL-21 verstärken synergistisch die Reaktionen von NK- und CD8+ T-Zellen wird am 9. November 2024 von Phoi Tiet, Senior Research Associate bei Equillium, präsentiert.
Das Abstract hebt das Potenzial von IL-15 und IL-21 hervor, die Aktivitäten von NK- und CD8-T-Zellen zu verstärken, indem sie deren Proliferation und zytolytische Funktion verbessern. Diese Kombination könnte ein vielversprechender Ansatz zur Stimulierung antitumoraler Immunreaktionen sein.
- Abstract accepted for presentation at a prestigious conference.
- Potential of IL-15 and IL-21 combination to enhance NK and CD8 T cell activities.
- None.
Combination of IL-15 and IL-21 robustly augments NK and CD8 T cell activity
Title: Interleukin (IL)-15 and IL-21 synergistically enhance NK and CD8+ T cell responses
Presenting Author: Phoi Tiet, Senior Research Associate, Equillium, Inc.
Abstract Number: 908
Location: Exhibit Halls A & B
Date: Saturday, November 9, 2024
The abstract highlights that cytokines are a focus of anti-cancer therapeutic development due to their central role in regulating anti-tumoral immune responses, and that data demonstrates that IL-15 and IL-21 synergistically augment NK and CD8 T cells activities, which further enhanced their proliferation and cytolytic function. With the ability to rescue T cell dysfunction, this cytokine combination could be a promising treatment approach to stimulating anti-tumor immune responses.
About Multi-Cytokine Platform and Multi-Cytokine Inhibitors EQ101 & EQ302
Our proprietary multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. This approach is expected to avoid the broad immuno-suppression and off-target safety liabilities that may be associated with other therapeutic classes, such as Janus kinase inhibitors. Many immune-mediated diseases are driven by the same combination of dysregulated cytokines, and we believe identifying the key cytokines for these diseases will allow us to target and develop customized treatment strategies for multiple autoimmune and inflammatory diseases.
Current platform assets include EQ101, a clinical stage, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9, and IL-15 for intravenous and subcutaneous delivery and EQ302, a preclinical stage, first-in-class, selective, bi-specific inhibitor of IL-15 and IL-21 for oral delivery.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; recently announced positive results from a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21; currently in pre-clinical development. The multi-cytokine platform: generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and exhibited positive results in a completed Phase 1b clinical study of patients with lupus/lupus nephritis in April 2024. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd., for the development and commercialization of itolizumab under an option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241007960831/en/
Investor Contact
Michael
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com
Source: Equillium, Inc.
FAQ
When will Equillium present their abstract at the Society for Immunotherapy of Cancer?
What is the title of Equillium's abstract accepted for the Society for Immunotherapy of Cancer conference?
What potential does the IL-15 and IL-21 combination have according to Equillium's abstract?
Where will the Society for Immunotherapy of Cancer conference take place in 2024?
